Repurposing radiosensitising medicines for radiotherapy: an overview
Journal article
RODRIGUEZ BERRIGUETE G. et al, (2024), BMJ Oncology
Antitumour effect of the mitochondrial complex III inhibitor Atovaquone in combination with anti-PD-L1 therapy in mouse cancer models.
Journal article
Rodriguez-Berriguete G. et al, (2024), Cell Death Dis, 15
Data from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models.
Journal article
Rodriguez-Berriguete G. et al, (2023), Clin Cancer Res, 29, 1631 - 1642
Supplementary Figure S1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S2 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S2 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S3 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S3 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S4 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S4 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S5 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S5 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S6 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S6 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Table S1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Table S1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Data from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Data from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)